Christina Y. Weng - research works

With a median 3.7 years of follow-up (range, 2.9-4.9), most patients (95%) reported ≥1 TEAE (387 events); 67% were procedure related, 9% were attributed to VN, and 82% were mild.

The area of CRA mostly localized to the retinotomy or bleb area, with 40% of eyes with CRA having atrophy outside the bleb area and highly correlated between fellow eyes (r=0.97; P<0.0001).

CRA risk was higher with automated foot pedal administration of VN (RR, 5.33; 95% CI, 1.27-22.40) and in patients with myopia (RR, 8.40; 95% CI, 1.16-60.69).

BCVA and FST were comparable between CRA and non-CRA eyes, although a subset of CRA eyes showed greater FST improvement at most time points up to Year 3.

Anatomically, the mean CFT at 1 year was significantly lower in the treated group (161 ± 65 μm) versus the observation group (278 ± 92 μm) (P = 0.001).

A second level I study compared half-dose verteporfin PDT versus 30%-dose verteporfin PDT and found that 94.6% in the half-dose PDT group had no SRF at 12 months compared with 75.4% in the 30%-dose PDT group (P = 0.004).

The noninferiority of the 30%-dose PDT compared with half-dose PDT was not demonstrated.

With respect to the primary outcome of visual acuity (VA), the VICI trial found no significant difference at 12 months: 79.5 letters in the placebo group and 80.4 letters in the eplerenone group (P = 0.24).

Thirty centers responded and reported genetic data from 33,834 patients (27,561 families).

Disease-causing variants were reported in 293 of 387 genes.

The top 100 genes accounted for the genetic cause of disease in 94.4% of patients.

In the 21 US sites, genetic testing was commonly obtained through sponsored programs (95%, FFB-My Retina Tracker Programs or Spark-ID Your IRD), whereas in the 9 non-US sites, genetic testing was commonly obtained using either patient- or public health system-funded testing pipelines.